王化, 邹强, 刘佩芳, 叶兆祥. 结合MR增强扫描测量肿瘤表观扩散系数值对大肝癌TACE的疗效评价[J]. 中国肿瘤临床, 2012, 39(16): 1204-1207. DOI: 10.3969/j.issn.1000-8179.2012.16.018
引用本文: 王化, 邹强, 刘佩芳, 叶兆祥. 结合MR增强扫描测量肿瘤表观扩散系数值对大肝癌TACE的疗效评价[J]. 中国肿瘤临床, 2012, 39(16): 1204-1207. DOI: 10.3969/j.issn.1000-8179.2012.16.018
shu
Hua WANG, Qiang ZOU, Peifang LIU, Zhaoxiang YE. Evaluation of the Therapeutic Effect of Transcatheter Arterial Chemoembolization in Massive Hepatocellular Carcinoma Using ADC Value Measurements Combined with Contrast-enhanced MR Imaging[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(16): 1204-1207. DOI: 10.3969/j.issn.1000-8179.2012.16.018
Citation: Hua WANG, Qiang ZOU, Peifang LIU, Zhaoxiang YE. Evaluation of the Therapeutic Effect of Transcatheter Arterial Chemoembolization in Massive Hepatocellular Carcinoma Using ADC Value Measurements Combined with Contrast-enhanced MR Imaging[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(16): 1204-1207. DOI: 10.3969/j.issn.1000-8179.2012.16.018
shu

结合MR增强扫描测量肿瘤表观扩散系数值对大肝癌TACE的疗效评价

Evaluation of the Therapeutic Effect of Transcatheter Arterial Chemoembolization in Massive Hepatocellular Carcinoma Using ADC Value Measurements Combined with Contrast-enhanced MR Imaging

    摘要
  • 摘要:
      目的  结合MR增强扫描, 探讨表观扩散系数(ADC)值测量在大肝癌经导管动脉化疗栓塞(TACE)疗效评价中的作用。
      方法  收集TACE治疗前及TACE后4~6周接受常规MRI、扩散加权成像(b=500, 0 s/mm2)及动态增强成像检查的大肝癌患者32例, 比较TACE前后各病灶ADC值, 并比较TACE治疗后肿瘤强化区和无强化区及与TACE前ADC值的差异。
      结果  TACE后整个病灶的ADC值(1.39±0.18)×10-3mm2/s较TACE前(1.23±0.19)×10-3mm2/s升高(P=0.016)。TACE后肿瘤无强化区的ADC值(1.80±0.32)×10-3mm2/s明显高于肿瘤强化区的ADC值(1.15±0.30)×10-3nm2/s(P < 0.001), 肿瘤强化区的ADC值明显低于TACE前的ADC值(P=0.048), 肿瘤无强化区的ADC值明显高于TACE前的ADC值(P < 0.001)。
      结论  ADC值有助于判断肿瘤活性, 分别测量肿瘤强化区和无强化区的ADC值能更准确地评估大肝癌对TACE的治疗反应。

     

    Abstract:
      Objectives  The therapeutic effect of transcatheter arterial chemoembolization (TACE) in massive hepatocellular carcinoma (HCC) using apparent diffusion coefficient (ADC) value measurements combined with gadolinium-enhanced magnetic resonance imaging (MRI) was evaluated.
      Methods  Routine, diffusion-weighted (b = 500, 0 s/mm2), and dynamic contrast-enhanced MRI were performed before and 4 wk to 6 wk after TACE in 32 patients with massive HCC. The ADC values in the whole tumor were measured and compared preand post-treatment The ADC values in the enhanced and unenhanced tumor portions were also measured after treatment. The obtained values as well as the ADC values before treatment in the enhanced and unenhanced portions were also compared.
      Results  The tumor ADC values significantly increased from (1.23 ± 0.19) × 10-3 mm2/s before TACE to (1.39± 0.18) x 103 mm2/s after TACE (P= 0.016). The ADC values in the unenhanced tumor portion (1.80 ±0.32) × 10-3 mm2/s were significantly greater than those in enhanced portion (1.15 ± 0.30) × 10-3 mm2/s after TACE (P < 0.001). The ADC values in the enhanced tumor portion were significantly lower than those before TACE (P= 0.048). The ADC values in the unenhanced tumor portion were significantly higher than those before TACE (P < 0.001).
      Conclusion  The ADC value may be beneficial in assessing tumor viability. Measuring the ADC value of the enhanced and unenhanced portions of a tumor may be more accurate in evaluating the therapeutic response of massive HCC to TACE.

     

    • HTML全文
    • 参考文献(12)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回